Exploring the Causal Relationship and Molecular Mechanisms Between Fasting Insulin and Androgenetic Alopecia: A Mendelian Randomization Study with Bioinformatics Analysis

This study used Mendelian randomization analysis to identify Scyllo-inositol and Alpha-ketoglutarate as potential protective factors and Heme and 2-palmitoylglycerophosphocholine as risk factors for androgenic alopecia, suggesting a causal link between these metabolites and the condition.

Among young male patients in a cardiac care setting, this study found that 54.4% had androgenetic alopecia, supporting the hypothesis that vertex pattern baldness could indicate a higher risk of cardiovascular events. Further research is needed to confirm these findings.

This study found that exosomes derived from bovine colostrum promoted hair growth in mice by activating the Wnt/β-catenin pathway, with effects similar to minoxidil but without adverse effects.

Natural products like saw palmetto, caffeine, melatonin, marine extracts, rosemary oil, procyanidin, pumpkin seed oil, and cannabidiol oil could potentially treat male hair loss.

This meta-analysis found that patients with androgenetic alopecia had a significantly higher prevalence of metabolic syndrome and poorer metabolic profiles compared to controls, especially among females, those with early onset, and individuals of African ethnicity.

This study investigated the relationship between early-onset androgenetic alopecia and metabolic syndrome in younger males, but the abstract does not report specific results.

This review discusses recent genetic findings on hormonal signaling pathways in androgenetic alopecia, reporting no new study results but highlighting the need for further investigation.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This study suggests a weak association between male-pattern baldness and some coronary heart disease risk factors, but does not support it as a strong indicator of coronary risk.

This review discusses female androgenetic alopecia, highlighting its diagnostic challenges and management strategies, but it reports no new results.

In this study, finasteride treatment for two years did not significantly reverse miniaturized hair follicles in men with male pattern hair loss, challenging the "reversal hypothesis" as 79 out of 113 miniaturized hairs remained unchanged.

This study observed that hair follicles in hair loss patients had increased levels of Propionibacterium acnes, potentially linked to elevated immune response gene expression in miniaturized hair follicles.

This study found that male patients with early-onset androgenetic alopecia were associated with metabolic syndrome, but not insulin resistance, compared to age-matched controls.

This study found that men with early-onset androgenic alopecia had a higher prevalence of cardiovascular risk factors, indicating that early screening for metabolic syndrome may be beneficial in this population.

This article reviews the cellular dynamics affecting dermal papilla size in androgenetic alopecia and suggests targeting DP size could improve therapies, but it presents no new clinical data.

This study found that patients with androgenetic alopecia had a higher prevalence of metabolic syndrome compared to healthy controls.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

This study suggests that the HDAC9 gene is a third susceptibility gene for male-pattern baldness, with significant associations found in both German and Australian samples.

This study suggests that genetic variants in the androgen receptor gene may predict which postmenopausal women with hair loss respond to finasteride therapy.

This article discusses the potential relationship between androgenic alopecia and insulin resistance but presents no new clinical findings, calling for further research on the topic.